tanruprubart
Monoclonal antibody
Evidence outlook · regulatory review
Guillain-Barré Syndrome: application submitted to EMA
Marketing authorisation application submitted to the EMA for tanruprubart in Guillain-Barré syndrome (2026-01-08). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Latest reported trial: NCT04701164 · Phase 3 · met primary endpoint · grade pending
Also in development:Huntington's Disease · Phase 2
Company guidance: data expected second half of 2026 (Annexon, Inc., 12 Aug 2026). “The currently ongoing open-label FORWARD study in the U.S. and Europe, which is designed to broaden Western experience with tanruprubart, and we anticipate initial PK, PD, biomarker and functional data in the second half of 2026 to supplement our comprehensive data package for tanruprubart in GBS.” Source ↗
Company guidance: regulatory filing expected Q4 2026 (Annexon, Inc., 9 Nov 2026). “Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04701164 NCT04701164 · Guillain-Barré Syndrome Registry: NCT04701164 | 3 | GBS Disability Score (GBS-DS) at Week 8; Number of Participants with Adverse Events (Through Month 6) 2024-04-20 | ANX005 (tanruprubart) 30 mg/kg: 2.4-fold improvement on GBS-DS at week 8 vs placebo, p = 0.0058. | not yet graded | link ↗ |
View 1 more trial
NCT07020819 NCT07020819 · Guillain-Barré Syndrome Registry: NCT07020819 | 3 | Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t) (Up to Day 15); Observed Time to Maximum Observed Serum Concentration (Cmax) (Tmax) of Tanruprubart (Up to Day 15) 2027-05-31 | In progress: results expected 31 May 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Complement C1q drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Huntington's Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tanruprubart: this drug | Phase 2 | Monoclonal antibody | Complement C1q | not yet graded | No reviewed efficacy summary in this indication | |
| Valbenazine (Ingrezza) | Approved | Small molecule | vesicular monoamine transporter 2 (VMAT2) | Partial signal | NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD). | |
| Vonaprument | Phase 3(overall) | Antibody fragment | Complement C1q | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Votoplam | Phase 3 | Small molecule | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| Ifezuntirgene Inilparvovec | Phase 1/2 | Gene therapy / editing | Huntingtin (HTT) gene | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-003 | Phase 1/2 | RNA / oligonucleotide | Huntingtin (HTT) | Weak signal | NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). | |
| Brezosiran | Phase 1 | RNA / oligonucleotide | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6662 | —(overall) | Gene therapy / editing | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow tanruprubart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent